ELVN
Enliven Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$44.25Close
$2.6BMarket cap
$15.14 – $61.1552-week range
Nov 11, 2026Next report
Highlights
Strengths
- Leading the market RS 80 · stronger than 80% of stocks over 12 months
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Far from its high 28% below its 52-week high
- Results soon Nov 11, 2026, in 10 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
28%
1wk
up 6.6%
price change
1mo
down 3.5%
price change
12-month return
up 85%
market up 11% ·
its own up 85%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
5.7×
price / book
Earnings yield
down 4.7%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 27%
return on equity
Free cash margin
—
-$70.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.2%
$1.87 a day · 2×ATR $40.52
RS
80 / 99
vs the universe
Trend
5 / 8
under the 150/200-day, under the 50-day, over 25% off the high
Relative volume
0.9×
vs 50-day average
Up/down volume
0.70
50 sessions
Implied move
—
no option chain · report Nov 11, 2026
Trend template · 5 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 21.5% over the year, from 49m to 59m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026-1% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$41.7M | -$24.8M | -$38.8M | -$83.5M | -$104.6M | -$119.7M |
| Net income | -$41.4M | -$24.7M | -$37.7M | -$71.6M | -$89.0M | -$103.7M |
| Earnings per share | — | -$10.73 | -$12.05 | -$2.01 | -$1.89 | -$1.83 |
| Free cash flow | -$37.4M | -$19.3M | -$32.7M | -$61.4M | -$73.2M | -$70.5M |
| Cash | $47.7M | $110.0M | $75.5M | $100.1M | $124.1M | $98.9M |
| Shareholders' equity | -$20.3M | -$42.9M | -$76.8M | $245.9M | $309.8M | $459.6M |
| Shares outstanding | 17.55m | 3.44m | 3.57m | 41.29m | 48.94m | 59.44m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 3, 2026 | Annual ↗ | Dec 31, 2025 | 62d |
| Nov 12, 2025 | Quarterly ↗ | Sep 30, 2025 | 43d |
| Aug 13, 2025 | Quarterly ↗ | Jun 30, 2025 | 44d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 13, 2025 | Annual ↗ | Dec 31, 2024 | 72d |
| Nov 13, 2024 | Quarterly ↗ | Sep 30, 2024 | 44d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
| May 14, 2024 | Quarterly ↗ | Mar 31, 2024 | 44d |
| Mar 14, 2024 | Annual ↗ | Dec 31, 2023 | 74d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 14, 2026 | Director or officer change · Regulation FD ↗ |
| Aug 5, 2026 | Results ↗ |
| Jun 12, 2026 | Material agreement · Regulation FD ↗ |
| Jun 11, 2026 | Regulation FD · Other events ↗ |
| Jun 10, 2026 | Charter or bylaws · Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Mar 3, 2026 | Results ↗ |
| Jan 7, 2026 | Director or officer change ↗ |
| Dec 11, 2025 | Director or officer change · Regulation FD ↗ |
| Nov 12, 2025 | Results ↗ |
| Aug 13, 2025 | Results ↗ |
| Jun 25, 2025 | Shareholder vote ↗ |